Portfolio data

Browse all portfolio data news

    Latest portfolio data news

    Show news from

    Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)

    Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress

    Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses

    Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

    Quell Therapeutics Advances QEL-001, its Multi-modular Engineered CAR-Treg Cell Therapy, into Efficacy Cohort of LIBERATE Phase 1/2 Trial in Liver Transplant Patients

    Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting

    Load more

    Search